Top Markets
Coin of the day
Quantum Genomics S.A. Quantum Genomics S.A.

Quantum Genomics S.A.

ALQGC
Rank in Stocks #37063
Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France,... Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France, in 2005, focuses on creating treatments for cardiovascular ailments. Its therapeutic approach utilizes the brain aminopeptidase A inhibition (BAPAI) platform, primarily addressing high blood pressure (hypertension) and heart failure. The company's key asset, firibastat, is currently undergoing a crucial Phase III study as a standalone therapy for hypertension and is also in clinical trials for heart failure. Additionally, Quantum Genomics is progressing QGC011 for hypertension in combination therapy, and further developing QGC006 and QGC606 to target both hypertension and heart failure.
Share Price
$0.07600875
Last synced: 2024-11-20
Market Cap
$2.06M
Change (1 day)
-0.51%
Change (1 year)
0.00%
Country
FR
Trade Quantum Genomics S.A. (ALQGC)

Category

P/S ratio for Quantum Genomics S.A. (ALQGC)
P/S ratio as of August 2026 TTM: 499.95K
According to Quantum Genomics S.A. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 499.95K. At the end of 2023 the company had a P/S ratio of 186.65.
P/S ratio history for Quantum Genomics S.A. from 2009 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 499.95K -0.53%
2024 502.59K 269,175.26%
2023 186.65 11,422.08%
2022 1.62 -95.60%
2021 36.83 -32.65%
2020 54.68 39.21%
2019 39.28 -99.83%
2018 22.77K 0.00%
2017 0.00 0.00%
2016 0.00 -100.00%
2015 406.74 397.85%
2014 81.70 -94.18%
2013 1.40K 15.20%
2012 1.22K 290.81%
2011 311.74 0.00%
2010 311.74 -14.29%
2009 363.69 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.17 -100.00%
US
10.13 -100.00%
NL
- -
CH
- -
KR
4.74 -100.00%
BE